Innate Pharma – Trademark Portfolio

Entity Type: 33

Innate Pharma holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ANKET, KIRTAMSY, and LONKIRLO.

117 avenue de Luminy

F-13009 Marseille

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

KIRTAMSY
KIRTAMSY
Registered 2023
LONKIRLO
LONKIRLO
Registered 2023
ANKET
ANKET
Registered 2021

Trademark Classifications

Innate Pharma's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Innate Pharma have?

Innate Pharma has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Innate Pharma file in?

Innate Pharma files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Innate Pharma's most well-known trademarks?

Innate Pharma's registered trademark portfolio includes well-known marks such as ANKET, KIRTAMSY, and LONKIRLO. These are among 3 currently registered trademarks in the portfolio.

What is Innate Pharma's trademark registration success rate?

Innate Pharma has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.